Immunotherapy has demonstrated a role in the therapeutic landscape of a small subset of patients with colorectal carcinoma (CRC) that harbor a microsatellite instability (MSI-H) status due to a deficient DNA mismatch repair (dMMR) system. The remarkable responses to immune checkpoint inhibitors (ICIs) are now being tested in the neoadjuvant setting in localized CRC, where the dMMR/MSI-H status can be found in up to 15% of patients, with remarkable results obtained in NICHE2 and 3 trials, among others. This case series aims to report our experience at a tertiary center and provide a comprehensive analysis of the possible questions and challenges to overcome if ICIs were established as standard of care in a neoadjuvant setting, as well as the potential role they may have as conversion therapy not only in locoregional advanced CRC but also in oligometastatic disease.
CITATION STYLE
San-Román-Gil, M., Martínez-Delfrade, I., Albarrán-Fernández, V., Guerrero-Serrano, P., Pozas-Pérez, J., Chamorro-Pérez, J., … Ferreiro-Monteagudo, R. (2024). Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1352262
Mendeley helps you to discover research relevant for your work.